Proximagen’s pipeline includes many programs which are in various stages of development across a number of therapeutic classes including CNS, inflammation, oncology and ophthalmology.
The acquisition will enable Upsher-Smith to research and develop pending programs of Proximagen, thus facilitating for its future growth.
Upsher-Smith president and chief executive officer Mark Evenstad said the acquisition of Proximagen adds significantly to the company’s scientific capabilities and supports the acceleration of its vision of becoming a leader in the CNS category.
"The combination of Upsher-Smith’s clinical development and commercialization expertise with Proximagen’s research and development platform provides the opportunity to further enhance our ability to bring new therapies to market to benefit patients," Evenstad added.